Sustained rheumatoid arthritis remission is uncommon in clinical practice

DSpace/Manakin Repository

Sustained rheumatoid arthritis remission is uncommon in clinical practice

Citable link to this page

 

 
Title: Sustained rheumatoid arthritis remission is uncommon in clinical practice
Author: Prince, Femke HM; Bykerk, Vivian P; Frits, Michelle; Iannaccone, Christine K; Shadick, Nancy Ann; Lu, Bing; Cui, Jing; Weinblatt, Michael Elliott; Solomon, Daniel Hal

Note: Order does not necessarily reflect citation order of authors.

Citation: Prince, Femke HM, Vivian P Bykerk, Nancy A Shadick, Bing Lu, Jing Cui, Michelle Frits, Christine K Iannaccone, Michael E Weinblatt, and Daniel H Solomon. 2012. Sustained rheumatoid arthritis remission is uncommon in clinical practice. Arthritis Research & Therapy 14(2): R68.
Full Text & Related Files:
Abstract: Introduction: Remission is an important goal of therapy in rheumatoid arthritis (RA), but data on duration of remission are lacking. Our objective was to describe the duration of remission in RA, assessed by different criteria. Methods: We evaluated patients from the Brigham and Women's Rheumatoid Arthritis Sequential Study (BRASS) not in remission at baseline with at least 2 years of follow-up. Remission was assessed according to the Disease Activity Score 28-C-reactive protein (DAS28-CRP4), Simplified Disease Activity Index (SDAI), and Clinical Disease Activity Index (CDAI) scores, and the recently proposed American College of Rheumatology (ACR)/European League against Rheumatism (EULAR) criteria for remission. Analyses were performed by using Kaplan-Meier survival curves. Results: We identified 871 subjects with ≥2 years of follow-up. Of these subjects, 394 were in remission at one or more time-points and not in remission at baseline, according to at least one of the following criteria: DAS28-CRP < 2.6 (n = 309), DAS28-CRP < 2.3 (n = 275), SDAI (n = 168), CDAI (n = 170), and 2010 ACR/EULAR (n = 158). The median age for the 394 subjects at entrance to BRASS was 56 years; median disease duration was 8 years; 81% were female patients; and 72% were seropositive. Survival analysis performed separately for each remission criterion demonstrated that < 50% of subjects remained in remission 1 year later. Median remission survival time was 1 year. Kaplan-Meier curves of the various remission criteria did not significantly differ (P = 0.29 according to the log-rank test). Conclusions: This study shows that in clinical practice, a minority of RA patients are in sustained remission.
Published Version: doi:10.1186/ar3785
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446437/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:10448731
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters